Immune checkpoint blockade (ICB) has become a standard of care in a subset of solid tumors. Although cancer survivorship has extended, rates of durable response of ICB remain poor; furthermore, cardiac adverse effects are emerging, which impact several mechanical aspects of the heart. Cardio-oncology programs implement a clinical assessment to curtail cardiovascular disease progression but are limited to the current clinical parameters used in cardiology. Pharmacogenomics provides the potential to unveil heritable and somatic genetic variations for guiding precision immunotherapy treatment to reduce the risk of immune-related cardiotoxicity. A better understanding of pharmacogenomics will optimize the current treatment selection and dosing of immunotherapy. Here, we summarize the recent pharmacogenomics studies in immunotherapy responsiveness and its related cardiotoxicity and highlight how patient genetics and epigenetics can facilitate researchers and clinicians in designing new approaches for precision immunotherapy. We highlight and discuss how single-cell technologies, human-induced pluripotent stem cells and systems pharmacogenomics accelerate future studies of precision cardio-oncology.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574958 | PMC |
| http://dx.doi.org/10.1093/hmg/ddaa137 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardiac Complications of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy.
Cardiol Clin
February 2025
Division of Cardiology, Department of Internal Medicine, Lahey Hospital and Medical Center, 41 Mall Road, Burlington, MA 01805, USA; Department of Medicine (Research), Cardio-Oncology Program, Lahey Hospital and Medical Center, 41 Mall Road, Burlington, MA 01805, USA. Electronic address:
Article Synopsis
- - Immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy have drastically improved cancer treatment but can lead to serious cardiovascular issues, notably myocarditis.
- - Diagnosis of ICI-myocarditis involves using a combination of biomarkers, imaging, and endomyocardial biopsy, while cytokine release syndrome (CRS) presents similar symptoms to distributive shock.
- - Effective management includes stopping the offending therapy, providing immunosuppression with corticosteroids for ICI-myocarditis, and using interleukin-6 antagonists for CRS, requiring close collaboration between oncologists and cardiologists for optimal care.
Peripheral biomarkers to assess risk, severity, and prognosis of immune checkpoint inhibitor-associated myocarditis: a retrospective clinical study.
Front Cardiovasc Med
October 2024
Department of Cardiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Background: Immune checkpoint inhibitor-associated myocarditis (ICI myocarditis) is an infrequent but potentially fatal immune-related adverse event. This study aimed to identify valuable indicators for risk prediction and evaluation of disease severity and outcomes.
Methods: A total of 79 patients with severe or mild ICI myocarditis and 158 controls without post-ICI immune-related adverse events were enrolled in this retrospective study.
The Good (Tumor Killing) and the Bad (Cardiovascular Complications) of Immunologic Checkpoint Inhibitors.
Curr Cardiol Rep
December 2024
Department of Medicine, Division of Cardiovascular Disease, Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Article Synopsis
- * New findings reveal that cardiac irAEs include a variety of pathologies beyond myocarditis, necessitating improved monitoring and early diagnosis through biomarkers and imaging.
- * A multi-disciplinary approach involving both cardiologists and oncologists is essential for managing patients on ICI therapy, along with updated guidelines to enhance care standards.
Immune checkpoint inhibitor-associated sick sinus syndrome and cardiogenic shock.
Int Cancer Conf J
October 2024
Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, 3-18-22 Honkomagome, Bunkyo-Ku, Tokyo 113-8677 Japan.
Article Synopsis
- Immune checkpoint inhibitors (ICI) have significantly improved cancer treatment, but they often have underestimated side effects, particularly related to heart health.
- A case study highlighted a 67-year-old Japanese man who experienced severe heart issues, including cardiogenic shock and sick sinus syndrome, shortly after starting a combination therapy with ipilimumab and nivolumab.
- To manage his condition, doctors first used a temporary pacemaker, followed by the implantation of a permanent pacemaker, which relieved his symptoms and enabled him to continue cancer treatment.
Sintilimab-induced myocarditis suspected in a patient with esophageal cancer and followed septic shock: case report and literature review.
Front Oncol
September 2024
Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Article Synopsis
- Immune checkpoint inhibitors (ICIs) like sintilimab are used to help fight cancer but can cause harmful side effects, including heart issues known as myocarditis.
- A 69-year-old man with cancer developed myocarditis after his treatment and initially felt fine, but then had serious problems like pneumonia and shock despite treatment.
- This case is special because it shows the importance of monitoring patients on sintilimab for heart issues and highlights the need to be aware of side effects from the steroids used to treat those problems.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!